Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in Glycogen Storage Disease Type Ib
NCT05960617Phase 2Withdrawn
- Sponsor
- Xinhua Hospital
- Start
- Jul 2023
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of empagliflozin in glycogen storage disease type Ib, sponsored by Xinhua Hospital. Primary endpoints: Absolute Neutrophil Count at 1 year and Occurrence of hypoglycemia at 1 year. Planned start Jul 2023; status: withdrawn.
02
Drugs
empagliflozin
03
Conditions
glycogen storage disease type Ib
Beyond the preview
Go deeper on NCT05960617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05960617.